A
Anixa Biosciences Inc
ANIXCIK 0000715446NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Oct 31
Period
FY 2025
Revenue
—
Net Income
$-10.93M
Total Assets
$16.08M
Equity
$15.16M
Shares Out
34.02M
Op. Cash Flow
$-7.17M
Business
Anixa Biosciences is a biotechnology company developing therapies and vaccines targeting critical unmet needs in oncology. The company is developing liraltagene autoleucel (lira-cel), a CAR-T cell therapy for ovarian cancer through subsidiary Certainty Therapeutics, and cancer vaccines targeting breast cancer, ovarian cancer, and other solid tumors through exclusive licenses with Cleveland Clinic and the National Cancer Institute. Clinical programs include Phase 1 trials for breast cancer vaccine (completed, Phase 2 planned) and CAR-T therapy for ovarian cancer (ongoing dose escalation), with additional vaccine discovery programs for lung, colon, and prostate cancers in early stages.
Summary from 10-K filed 2026-01-12
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Revenue | — | — | 210,000 | — | 512,000 | |
| Research and development expenses (including non-cash stock-based compensation expenses of $1,560 and $1,859, respectively) | 5 | 6 | 5 | 7 | 6 | |
| General and administrative expenses (including non-cash stock-based compensation expenses of $2,250 and $2,923, respectively) | 7 | 7 | 6 | 7 | 7 | |
| Total operating costs and expenses | 12 | 14 | 11 | 14 | 14 | |
| Loss from operations | −12 | −14 | −11 | −14 | −13 | |
| Interest income | 673,000 | 1 | 1 | 104,000 | 2,000 | |
| Net loss | −11 | −13 | −10 | −14 | −13 | |
| Less: Net loss attributable to noncontrolling interest | −101,000 | −144,000 | −119,000 | −176,000 | −174,000 | |
| Net loss attributable to common shareholders | −11 | −13 | −10 | −14 | −13 | |
| Basic (per share) | −0.34 | −0.39 | −0.32 | 0.45 | −0.45 | |
| Diluted (per share) | −0.34 | −0.39 | −0.32 | 0.45 | — | |
| Basic (shares) | 32,454 | 31,898 | 30,980 | 30,374 | — | |
| Diluted (shares) | 32,454 | 31,898 | 30,980 | 30,374 | 29 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 1 | 915,000 | 12 | 29 | |
| Shortterm investments | 14 | 19 | 23 | 17 | 7 | |
| Receivables | — | 173,000 | 270,000 | 46,000 | — | |
| Prepaid expenses and other current assets | 713,000 | 1 | 1 | 467,000 | 276,000 | |
| Total current assets | 16 | 21 | 25 | 30 | 36 | |
| Operating lease right-of-use asset | 193,000 | 229,000 | 166,000 | 212,000 | 254,000 | |
| Total assets | 16 | 22 | 26 | 30 | 36 | |
| Accounts payable | 165,000 | 525,000 | 206,000 | 265,000 | 136,000 | |
| Accrued expenses | 2 | 2 | 2 | 2 | 1 | |
| Operating lease liability | 41,000 | 29,000 | 52,000 | 46,000 | 39,000 | |
| Total current liabilities | 2 | 3 | 2 | 2 | 1 | |
| Operating lease liability, non-current | 163,000 | 203,000 | 123,000 | 175,000 | 220,000 | |
| Total liabilities | 2 | 3 | 2 | 2 | 1 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock, value | — | — | — | — | — | |
| Common stock, par value $.01 per share; 100,000,000 shares authorized; 33,013,829 and 32,196,862 shares issued and outstanding as of October 31, 2025 and 2024, respectively | 330,000 | 322,000 | 311,000 | 309,000 | 301,000 | |
| Additional paid-in capital | 267 | 260 | 252 | 247 | 240 | |
| Accumulated deficit | −252 | −241 | −228 | −218 | −205 | |
| Treasury stock, 2,000 shares at cost as of October 31, 2024 | — | −6,000 | — | — | — | |
| Total shareholders equity | 15 | 20 | 24 | 29 | 35 | |
| Noncontrolling interest (Note 2) | −1 | −1 | −966,000 | −847,000 | −671,000 | |
| Total equity | 14 | 19 | 23 | 28 | 35 | |
| Total liabilities and equity | 16 | 22 | 26 | 30 | 36 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-10-31 | FY 2024 2024-10-31 | FY 2023 2023-10-31 | FY 2022 2022-10-31 | FY 2021 2021-10-31 |
|---|---|---|---|---|---|---|
| Stock option compensation to employees and directors | 4 | 4 | 4 | 6 | 8 | |
| Stock options issued to consultants | 129,000 | 125,000 | 221,000 | 655,000 | 555,000 | |
| Common stock issued to consultants | — | 255,000 | 92,000 | 97,000 | — | |
| Amortization of operating lease right-of-use asset | 36,000 | 37,000 | 46,000 | 42,000 | 60,000 | |
| Amortization of discount on held-to-maturity securities | −143,000 | — | — | — | — | |
| Receivables | 173,000 | 97,000 | −224,000 | −29,000 | — | |
| Prepaid expenses and other current assets | 552,000 | −23,000 | −775,000 | −208,000 | 36,000 | |
| Accounts payable | −360,000 | 319,000 | −59,000 | 129,000 | −96,000 | |
| Accrued expenses | −185,000 | 176,000 | 44,000 | 631,000 | 193,000 | |
| Operating lease liability | −28,000 | −43,000 | −46,000 | — | — | |
| Net cash used in operating activities | −7 | −7 | −6 | −6 | −5 | |
| Disbursements to acquire short-term investments | −44 | −64 | −44 | −22 | −16 | |
| Proceeds from maturities of short-term investments | 49 | 68 | 39 | 12 | 13 | |
| Net cash provided by investing activities | 5 | 4 | −6 | −11 | −4 | |
| Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $183 and $168, for the years ended October 31, 2025 and 2024, respectively | 2 | 3 | — | — | 11 | |
| Proceeds from sale of common stock pursuant to employee stock purchase plan | 7,000 | 10,000 | 13,000 | 13,000 | 6,000 | |
| Net (costs) proceeds from exercise of stock options | −105,000 | 456,000 | — | — | — | |
| Disbursements for purchases of treasury stock | — | −6,000 | — | — | — | |
| Net cash provided by financing activities | 2 | 3 | 366,000 | 452,000 | 32 | |
| Net (decrease) increase in cash and cash equivalents | −27,000 | 356,000 | −11 | −17 | 23 | |
| Cash proceeds from interest income | 686,000 | 1 | 838,000 | 23,000 | — | |
| Modification to operating lease right-of-use asset | — | −100,000 | — | — | — | |
| Modification to operating lease liability | — | 100,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Anixa Biosciences Inc's CIK number?
Anixa Biosciences Inc's SEC CIK number is 0000715446 (715446). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Anixa Biosciences Inc's SEC filings?
All of Anixa Biosciences Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.